Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis

Stallergenes Greer

Status: Completed

Conditions: Allergy

Treatments: Drug: Oralair

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02295969

SL74.14

Details and patient eligibility

About

Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.

Full description

The purpose of this study is to further describe the safety and tolerability of ORALAIR tablets in children 5 to 9 years of age with grass-pollen-induced allergic rhinitis with or without conjunctivitis.

Patients are followed for safety and tolerability during the first 30 treatment days.

Enrollment: 307 patients

Sex: All

Ages: 5 to 9 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Allergen immunotherapy naive male or female outpatients aged 5 to 9 years (inclusive) prescribed ORALAIR.

Exclusion criteria

Patients already participating in a clinical trial.